

Personal

Date of Birth: July 19, 1970

Nationality: Libyan

Marital Status: Married

Number of Children: Two

Contact Information

Mobile: (218) 914461615

Home: (218) 924311931

E-mail: elzagheid@yahoo.com

E-mail: elzagheid@btc.org.ly

Adam Elzagheid,
MD, PhD, Docent



Curriculum Vitae

20 Years of Teaching, Research, Administrative, and managerial Experience:

Over the last Twenty years at Turku University, Department of Pathology and Oncology (Turku, Finland), University of Benghazi, Department of Pathology (Benghazi, Libya), Biotechnology Research Center & University of Tripoli (Tripoli, Libya), I have gained excellent teaching, research, administrative and managerial experience.

- Research & development experience in the prognostication of tumor biomarkers in solid tumors (such as; breast, colorectal, and prostate tumors).
- Professional experience in curriculum development, articulations, accreditation, professional certification, and Training.
- Teaching experience in general and systemic pathology, Research Methodology, molecular pathology, Lab techniques.

ACADEMIC QUALIFICATIONS

Professor (01/15)

Libyan Agency for Research, Science, and Technology, Tripoli, Libya
University of Tripoli, Department of Pathology, Tripoli Libya

Visiting Professor (01/15)

University of Tripoli, Faculty of Medicine, Department of Pathology, Tripoli Libya

Adjunct professor (Docent) (05/13)

Pathology Department, University of Turku, Finland

Post-doc (02/2004- 08/2007)

Oncology and Radiotherapy Department, University Central Hospital, Turku, Finland

Doctorate Degree (01/2004)

Pathology Department, University of Turku, Finland

M.B.CH.B (1996)

Faculty of Medicine, University of Benghazi (formal name; Al-Arab Medical University), Benghazi, Libya

PROFESSIONAL EXPERIENCE

- Chairman of the Board of Directors of the National Center for Disease Control
- Member of the Board of Directors of the Medical Training Deanship Council
- **Current Position: Director-General**, Biotechnology Research Center, and visiting Professor at University of Tripoli, Tripoli, Libya
- Deputy Director-General, Biotechnology Research Center, Tripoli, Libya
- Professor, Biotechnology Research Center, Tripoli, Libya

- Chairman of the Board of National Center Disease Control, Tripoli
- Full Professor, Libyan Agency for Research, Science, and Technology, Tripoli, Libya
- Associate professor, Department of Pathology, University of Benghazi, Benghazi, Libya
- Former Dean, Faculty of Medicine, University of Benghazi, Benghazi, Libya
- Deputy, Libyan Authority for Research, Science, and Technology, Benghazi Branch, Benghazi, Libya
- Head, Department of Microbiology and Parasitology, University of Benghazi, Benghazi, Libya
- Adjunct professor, Turku University, Turku, Finland
- Head, Medical Research Unit, Benghazi, Libya
- Assistant Professor, Department of Pathology, University of Benghazi, Benghazi, Libya
- Head, Department of Pathology, University of Benghazi, Benghazi, Benghazi, Libya
- Post-graduate study Coordinator, Department, University of Benghazi, Benghazi, Libya
- Lecturer, Department of Pathology, University of Benghazi, Benghazi, Libya
- Post-doc, Oncology & Radiotherapy Department, Turku University Central Hospital, Finland
- Research associate, Department of Pathology, University of Turku, Finland
- SHO, Medical Faculty, Benghazi University

HONORS AND AWARDS

- National Academy for Scientific Research, Tripoli, Libya 2010-2017
- Turku University Foundation 2007
- Cancer Society of South-West Finland, Turku 2005
- Turku University Foundation 2005
- Turku University Foundation 2003
- Turku University Foundation 2002
- Cancer Society of South-West Finland, Turku 2002
- Turku University Central Hospital Foundation 2001
- Paulo Foundation 1999.

TEACHING EXPERIENCE

- Teaching medical students: general and systemic pathology
- Teaching dental students: general and systemic pathology
- Teaching postgraduate students: general and systemic pathology

-Basic Pathology (Robbins) for medical students:

- General Pathology:
 - Cell injury, adaptation, and death
 - Disease of Immunity
 - Neoplasia

Disease of Organ Systems

- The blood vessels
- The heart
- The lung and the Upper Respiratory Tract
- Breast diseases
- The Oral Cavity and the Gastrointestinal Tract

Basic Pathology (Robbins) for Dental students:

General Pathology:

- Acute and Chronic Inflammation
- Hemodynamic Disorders, Thrombosis, and Shock
- Genetic and Environmental Diseases

Pathologic Basis of Disease (Robbins and Cotran) for postgraduate students:

General Pathology:

- Cell injury, adaptation, and cell death
- Disease of Immunity
- Neoplasia

Disease of Organ Systems

- The blood vessels
- The heart
- The Endocrine System
- Female Genital Tract
- Teaching postgraduate students: Research Methodology
- Teaching postgraduate students: Molecular Pathology

RESEARCH INTEREST

Quantitative Pathology, Molecular Pathology, Prognostic markers of breast cancer, Colorectal cancer, Prognostication models, Immunohistochemical prognostication, Immunohistochemistry Automated analysis, And DNA cytometry.

SUPERVISION, EXAMINATION, AND EDITORIAL ACTIVITIES

(1998-2017) Published articles and abstract in peer-reviewed International Journals and Congresses.

Acting as a reviewer in different peer-reviewed international Journals (such as; Tumor Biology, Histopathology, Oncology basil, Ibnosina J Med BS, BMC Cancer, and Libyan Journal of Medicine).

Supervisor, internal, and external examiner for postgrad students:

(2009) **Khaled M.I. Elgehani** "Angiogenesis in urinary bladder carcinoma; Histopathological and Immunohistochemical" (**Internal Examiner**).

(2012) **Amel Y. I. Eljazwey** "Pathological study of Wlim's Tumor" (**Supervisor**).

(2012) **Raja F.H. Al Jafil** "Application of adhesion molecules (E-cadherin) as a Prognostic marker in colorectal cancer" (**Supervisor**).

(2012) **Mabroka A. Attia** "Prognostic Significance of Estrogen and progesterone Receptors in Female Breast Cancer" (**Internal Examiner**).

(2012), **Taghrid H. M. Bengallol** "Expression of e-cadherin in prostatic carcinoma: prognostic significance" (**Supervisor**).

(2013) **Warda M. Musbah Said** "Application of adhesion molecules (B-catenin) as a prognostic marker in prostate cancer" (**Internal Examiner**).

(2013) **Hiam Mohamed Elnahwi** "Evaluation of Survivin expression in Renal Cell Carcinoma by Immunohistchemistry and study it's correlation with clinic-pathological features and prognosis" (**Co-supervisor**).

(2013) **Rania A. ElSharif** "Prognostic Significance and Clinic-pathological Association of COX-2 Expression in Colorectal Carcinoma of Libyan Patients" (**Co-supervisor**).

(2013) **Intesar Salem Alhadar** "Evaluation of P53 and Ki-67 expression in basal cell carcinoma by Immunohistochemistry and study its correlation with clinicopahtological

features and prognosis" (**Co-supervisor**).

(2015) **Monsef Awad El-Seed El-Mansour** “Comparative Histopahtological and Immunohistochemical studies on Mammary Gland tumomrs in Human and Canines” (**External Examiner**).

(2016) **Khadija Milod Slik**. “Uterine Smooth Muscle Tumors: clinicopathological evaluation” Research study for second part of Libyan board of pathology. (**Reviewer**).

(2016) **Nagah Ragab Markus**. “Nasopharyngeal carcinoma association with Ebstin-Barr Virus” Research study for second part of Libyan board of pathology. (**Reviewer**).

(2019) **Mariam Ali Mohamed Hussein** “the effect of Fenugreek seeds (Trigonella Fewnum-graecum) extract on pancreatic beta cells of streptozotocin diabetic rats” (**External Examiner**). **Department of Zoology, Faculty of Science, University of Tripoli (Resolution 3/2019 dated on 08-01-2019)**.

(2019) **Ahlam Masaud B Ellafi**“Identification of alpha-galactosidase A gene mutation I a Libyan family with Fabry' disease” (**External Examiner**). **Department of Histology and Genetics, Faculty of Medicine, University of Tripoli (Resolution 1286/2019 dated on 12-10-2019)**.

INVITED TALKS AND PRESENTATIONS

Oral presentation in the European pathology and Infectious disease Congress, Helsinki, Finland	11/18
Poster presentation in the 14 th International Congress on Surgical Pathology & Cancer Diagnosis, Rome, Italy	05/18
Poster presentation in the 27 th European Congress of Pathology Serbia, Belgrade	09/15
Poster presentation in the 25 th European Congress of Pathology Lisbon, Portugal.	08/13
Poster presentation in the 24 th European Congress of Pathology Prague, Czech Republic.	09/12
Oral presentation in the 22 nd Congress of the International Academy of Pathology- Arab Division	12/10
Poster presentation in the 4 th Congress of African Oncology Institute	01/09

Poster presentation in the 27 th International Congress of the IAP	10/08
Poster presentation in the 4 th International Symposium on Targeted Anticancer Therapies, Amsterdam, the Netherlands	03/07
Poster presentation in ASCO Gastrointestinal cancers Symposium Orlando, Fl, USA, 2007	01/07
Poster presentation in The International Conference of Pathology Montreal, Canada	09/06
Oral presentation in the 2 nd JSP (JORDAN SOCIETY OF PATHOLOGY) Conference 2006 Aman	09/06
Poster presentation in the 16 th Annual BioCity Symposium, Turku, Finland.	08/06
Poster presentation in the 2 nd Intercongress of the European Society of Pathology, Ioannina, Greece	05/06
Poster presentation in the 4 th International Symposium on Targeted Anticancer Therapies, Amsterdam, the Netherlands	03/06
Poster presentation in the 20 th European Congress of Pathology, Paris, France.	09/05
Poster presentation in the 3 rd International Symposium on Targeted Anticancer Therapies, Amsterdam, the Netherlands.	03/05
Poster presentation in the 14 th Annual BioCity Symposium	08/04
Poster presentation in the International Conference on Applied Genomics “9 th ESACP/ 16 th ISDQP meeting” Amsterdam, The Netherlands.	10/03
Poster presentation in the 13 th Annual BioCity Symposium, The 7 th Symposium of the Finnish Cancer Institute (CANCER), Turku, Finland	08/03
Poster presentation in the 18 th European Congress of Pathology, Berlin, Germany	09/01
Poster presentation in The XI th Annual BioCity Symposium “Redox regulation of Cellular Function” Turku, Finland.	08/01
Poster presentation in 7 th Congress of the European Society for Analytical Cellular Pathology, Caen, France.	04/01

MEMBERSHIPS

International academy of Pathology, Arab division	2010- to date
European Society of Pathology	2005- to date
European Association for Cancer Research	2005-2007
Finnish Medical Society (Duodecim)	2005-2007
Libyan Medical Society-UK	2004- to date
Libyan Syndicate- Benghazi	1998-to date

OTHER SKILLS

COMPUTER

Word, Power Point, Excel, SAS (statistical software).

TECHNICAL SKILLS

PCR (polymerase chain reaction), Immunohistochemistry (Ventana), DNA Cytometry (Ahrens Cytometry Analysis System), Morphometry (Prodit, version 3), some experience in DNA sequencing and SSCP (single strand conformation polymorphism), Light and Electron microscope.

LANGUAGES

Arabic (mother tongue) and English (fluent)

PUBLICATIONS, IMPACT FACTORS, CITATIONS, H-INDEX:

<u>Type of Publications</u>	<u>Number of Publications</u>
Articles in International peer-Reviewed Journals	58
Abstracts	13
Other publications	4
Total:	75

<u>Citation Source</u>	<u>Number of Citations</u>
Research-Gate	652
RG-Score	31.01
Google Scholar	1158
h-index	18
i10-index	22

<u>Type of Publications</u>	<u>Impact Factor</u>
Articles in International peer-Reviewed Journals	65
Abstracts	75
Total	140

PUBLICATIONS

1. Salah, Khaled & Glessa, Sara & Emaetig, Fatma & Abudabbous, Hisham & Jebril, Abdulla & Elnattah, Nabil & Syrjänen, Kari & Jaber, Mamduh & Elrabie, Abdulsalam & Elfagieh, Mohamed & **Elzagheid, Adem** & Zaggut, Abdulhakim. (2021). Prognostic Significance of Survivin and Livin Expression in the Primary Breast Cancer and Their Lymph Node Metastases. **Journal of Surgical Oncology (2021). 1-10.**
2. Alhudiri, Inas & Ramadan, Ahmad & Ibrahim, Khaled & Eljilani, Mouna & Aboud, Adel & Salem, Mohamed & Elgheriani, Hajer & **Elzagheid, Adem**. (2021). Whole-genome sequencing of SARS-COV-2 reveals a substantially lower frequency of the UK variant than previously announced in Libya.
3. Zakarya Abusrewil, Inas M Alhudiri, Hamza Hussein Kaal, Salah Edin El Meshri, Fawzi O. Ebrahim, Tarek Dalyoum, Abdussamee A Efrefer, Khaled Ibrahim, Mohammed Ben Elfghi, Suleiman Abusrewil, **Adam Elzagheid**. Time scale performance of rapid antigen testing for SARS-COV-2: evaluation of ten rapid antigen assays. **Journal of Medical Virology 2021**
4. Mouna Mohamed ElJilani, Mohamed Abdusalam, Adel Abdalla, Tarek Dalyoum, Salah Ahmad, Inas Alhudiri, **Adam Elzagheid**. Performance evaluation of seven commercial real-time polymerase chain reaction assays for SARS-COV-2 detection. **Libyan Journal of Medical Sciences 2021:5**
5. Eman Gusbi, Farag I Eltaib, Abraham F Abraham, Walid M Benbubaker, Inas M Alhudiri, Sameera Ahmad Al-dabea, Hafsa A Alemam, Nada Elgriw, Adel M Elshukri, Ahmed O Hamil, Latifa bettamer, Nabil Enattah, **Adam Elzagheid**. Cancer incidence in Southern Libya: Updated report from 2016 to 2018. **Libyan Journal of Medical Sciences 2021:5**
6. **Elzagheid, Adem** & Libya, Tripoli & Al-Fituri, Omran. (2020). Ministry of Education Authority of Natural Science Research and Technology The Prognostic and Predictive Value of Immunohistochemical Markers in Stage II Colorectal Cancer Special Reference to E-cadherin, MUC2, Cyclooxygenase-2, Protein phosphatase methylesterase-1 (PME-1), Neurofibromin, and Protein phosphatase 2A (PP2A) inhibitor CIP2A. Prepared By.
7. Omar, Fawzi & Abolayha, Abdul & **Elzagheid, Adem** & Abosrer, Fadella & El Meshri, Salah Edin. (2020). Isolation of primary mice splenocytes for in vitro research. Alexandria Journal of Veterinary Sciences. 64. 13. 10.5455/ajvs.82519.
8. Inas M Alhudiri, Fawzi O. Ebrahim, Ahmed Sassi, Salah Edin El Meshri, Abdulmunam A. Fella, Ammar K. Asloug1, Adel M. Elmaghrabi, Dhastagir Sheriff, **Adam I. Elzagheid**. Overview of Epidemiology, Pathogenesis and

Clinical Aspects of COVID-19: A Libyan Perspective. *Journal of Veterinary Sciences. AJVS*. Vol. 64 (2): 9-12. Jan 2020. DOI: 10.5455/ajvs.82519.

9. Hafsa Emmam, Nabil Enattah, **Adam Elzagheid**. Evaluation of relationship between vitamin D deficiency and obesity In Diabetic Mellitus Libyan Patients. **(Submitted)**. 5th International Conference on Engineering and Applied Sciences, Prague, Czech Republic. March 2020.
10. Ashammakhi N, Mohamed Elmisrati, **Elzagheid A**. Cancer modeling-on-a-chip **SMALL (In press)**. November 2019. *Small* 15(50):1901985.
DOI: 10.1002/sml.20190198.
11. Alhudiri I, Green A, Nolan C, Ellis I, Robertson J, Chapman C **Elzagheid A**. Cathepsin D: a neglected breast cancer prognostic marker. **Breast Cancer Res Treat. (Submitted)**.
12. Elhoni A, El Darat T, Elkwafi R, Ramse W, **Elzagheid A**, Sheriff DS. Gross Hematuria and prostatic cancer in Libyan patients. **JAMPS,2019, 21(20):1-5**.
13. Ebrahim F, Fellah M, Elzagheid A. Purification of Lactoferrin from Camel colostrum and Protein Profiles of Camel and Bovine Milk. **AJVS. 2019, 60(2):67-70**.
14. Alhudiri I, Green A, Nolan C, Ellis I, Robertson J, Chapman C **Elzagheid A**. Lamin A/C a novel potential prognostic marker in early operable primary breast cancer. **Breast Cancer Res Treat. 2019 Jan 4**.
15. Gleesa S, Emaetig F, Alragig M, Syrjanen K, Jaber M, Obida S, Elfagieh M, **Elzagheid A**. Prognostic significance of survivin and livin expression in the primary breast cancer and their lymph node metastases. **Submitted**.
16. Ashammakhi N, **Elzagheid A**. "Organ-on-a-chip. New Tool for Personalized Medicine". **Journal of Craniofacial Surgery, 2018 Jun;29(4):823-824**.
17. Elzouki I, Beyased T, Altrjoman F, Elmarghani A, Abubaker KS, **Elzagheid A**. Cancer incidence in Western Region of Libya. Report of the Year 2009 from Pathology-Based Cancer Registry of Tripoli. **Libyan J Med Sci 2018;2:45-50**
18. Birkman EM, **Elzagheid A** Avoranta T, Korkeila E, Syrjänen K, Westermarck J, Sundström J. Cancerous inhibitor of protein phosphatase 2A (CIP2A) protein expression predicts a poor clinical outcome in colorectal cancer. **CANCER MEDICINE**. 2018 Mar;7(3):698-706.
19. ElMoaket M, Emaetig F, Abdulmalik F, Torjoman F, Enattah N, Marck EV, **Elzagheid A**. Immunophenotype and prevalence of H.pylori infection. **Ibnosina J Med Biomed Sci 2018;10:94-8**
20. Said W, Emaetig F, y El Gehani K, Eldarat T, Buhmeida A, **Elzagheid A**, and El-Faitori O. Over-expression of B-catenin is associated with high grade of prostatic cancer in Libyan patient. **African Journal of Urology 2017,23:133-138**.
21. Ashammakhi N, **Elzagheid A**, Elbabour M. Fast and Efficient Science

- Communication. **Ibnosina J Med BS (2017), 9(2):50-51.**
22. Beyased T, Altrjoman F, Enattah N, Eltaib F, Ashammakhi N, **Elzagheid A.** Cancer incidence in Western Libya. First results from Tripoli Medical Center. **Ibnosina J Med BS (2017), 9(2):137-145.**
 23. Ashammakhi N, Elkhammas M, **Elzagheid A.** Organ Preservation Can Do More. **Ibnosina J Med BS (2017), 9(5).**
 24. Ebrahim F, Fellah M, **Elzagheid A,** Enattah N, Karem F, Abosrer F, Mostafa K, Alwaer O, Hassan A, Farhat M, Bredan A, Elmarzugi N. Seroprevalence of Foot and Mouth Disease, Blue Tongue Disease and Camel Brucellosis in Animals Imported into Libya. **AJVS. Vol. 54: 97-100. 2017.**
 25. **Elzagheid A,** Emaetig F, Wesam Elzawy, Altrjoman F, Syrjanen K, Laato M, Collan Y, and Pyrhonen S. Neurofibromin Expression is Associated with Aggressive Disease and Poor Outcome in Colorectal Carcinoma. **Anticancer Research 2016, 36: 5301-06.**
 26. Bengallol T, El-Fituri O, Sassi S, BenKhaial F, Gehani K, Buhmeida A, **Elzaagheid A.** Expression of E-cadherin in Prostatic Carcinoma: Prognostic Significant. **J Cancer Prev curr Res 2016, 4(3):00119**
 27. Eltaib F, Boris B, Abubaker K, Enattah N, **Elzagheid A.** Heat shock proteins 90 as a novel target for cancer. **Medical Science, 6(3) 2016.**
 28. Kaur A. **Elzagheid A,** Birkman EM, Avoranta T, Korkeila E, Syrjänen K, Westermarck J, Sundström J. Protein phosphatase methylesterase (PME-1) expression predicts a favorable clinical outcome in colorectal cancer. **Cancer Medicine 2015**
 29. ElSharif R, Emaetig F, Aljafil R, Elshieky A, Bugarra F, Buhmeida A, El-Faitori O, and, **Elzagheid A.** Cyclooxygenase-2 (COX-2) expression in Libyan patients with colorectal carcinoma with lymphovascular invasion. **Global Journal of Pathology and therapeutics 2014;2(2):033-038 .**
 30. Aljafil R, F, Sassi S, El Hasadi I, El Gehani K, Buhmeida A, El-Faitori O, D.S. Sheriff, and **Elzagheid A.** E-cadherin expression in Libyan patients with colorectal carcinoma. **Medicine Journal 2014;2(1):1-7.**
 31. **Elzagheid A,** Emaetig F, Al-Kikhia L, Buhmeida A, Al-Fituri O, Syrjanen K, Laato M, Collan Y, and Pyrhonen S. High Cyclooxygenase-2 Expression Is Associated With Advanced Stages in Colorectal Cancer. **Anticancer Research 2013; 8(33):3137-43.**
 32. Emaetig F, El Gehani K, El nahwie H, El Hasadi I, Sassi S, Al-Ammari S, Buhmeida A, and **Elzagheid A.** Survivin Expression in Renal Cell Carcinoma and Its Correlation with Clinicopathological Parameters. **Journal Interdisciplinary Histopathology 2013; 1(4):184-94.**
 33. **Elzagheid A,** Emaetig F, Buhmeida A, Al-Fituri O, Syrjanen O, Laato M, Collan Y, Pyrhonen S. MUC-2 expression predicts disease recurrence and survival in colorectal carcinoma. **Tumor Biology 2013; 34(2):621-8.**
 34. Huda Gargum, Abd El-Naser Al Zoki, Idris F. El-Barassi, Saleh Saeed Muftah, Faraj El Shaari, Masaud Jumma, **Adam Elzagheid** and Awad G. Abdellatif. **INVESTIGATION ON THE ACUTE AND SUBACUTE TOXICITY OF ALHAGI GRAECORUM IN EXPERIMENTAL ANIMALS.**

International Journal of Applied Biology and Pharmaceutical Technology 2013, 4(3): 202-209.

35. El Gehani K, Al-Kikhia L, Syrjanen K, Al-Fituri O, and **Elzagheid A**. Over-Expression of HER-2 is Associated with the Stage in Carcinomas of the Urinary Bladder. **Libyan J Med**. 2012;7.
36. **Elzagheid A**, Buhmeida A, Laato M, Al-Fituri, O, Collan Y, Syrjanen K, Pyrhonen S. Loss of E-cadherin predicts disease recurrence and shorter survival in colorectal carcinoma. **APMIS**. 2012;120(7):539-48.
37. Gehani K, Al-Kikhia L, Mansuri N, Syrjanen K, Al-Fituri O, and **Elzagheid A**. Angiogenesis in urinary bladder carcinoma as defined by microvessel density (MVD) after immunohistochemical staining for Factor VIII and CD31. **Libyan Journal of Medicine** 2011; 6.
38. Abdalla F, Boder J, Buhmeida A, **Elzagheid A** and Collan Y. Image DNA in FNABs of Libyan breast disease. **Anticancer Research** 2010; 30(1):175-82.
39. Bosrewill H, **Elzagheid A**, Syrjanen K, Musa A. Incidence and management of breast cancer in Libyan females in Eastren part of Libya. **Jamahiryia Medical Journal** 2010;10(1): 17-21.
40. Zhou Q, Talvinen K, Sundström J, **Elzagheid A**, Pospiech H, Syvaaja J, Collan Y. Mutations and/or polymorphisms in the second largest subunit of DNA polymerase ϵ in human colorectal cancer: association with clinical and immunohistochemical prognostic features. **Cancer Genomics & proteomics** 2009;6(6):297-304.
41. Ibrahim N, **Elzagheid A**, El-Hashmi H, Syrjanen K, Alhakim S. The potential value of EGFR and p53 immunostaining in urinary bladder tumor. **Libyan Journal of Medicine** 2009; 4(4):143-5.
42. Buhmeida A, Hilska M, **Elzagheid A**, Laato M, Collan Y, Syrjanen K, Pyrhonen S. DNA image cytometry predicts disease outcome in stage II colorectal carcinoma. **Anticancer Research** 2009;29(1):99-106.
43. Abdalla F, Boder J, Buhmeida A, Hashmi H, **Elzagheid A**, Collan Y. Nuclear morphometry in FNABs of breast disease in Libyans. **Anticancer Research** 2008;28(6B):3985-9.
44. **Elzagheid A**, Buhmeida A, Korkeila E, Collan Y, Syrjanen K, Pyrhonen S. Up-regulation of alfa-catenin is associated with increased lymph node involvement in colorectal cancer. **World Journal of Gastroenterology** 2008;14 (31):4903-8.
45. **Elzagheid A**, Buhmeida A, korkeila E, Collan Y, Syrjanen K, Pyrhonen S. Nuclear β -catenin expression as a prognostic factor in advanced colorectal cancer. **World Journal of Gastroenterology** 2008;14 (24):3866-71.
46. **Elzagheid A**, Collan Y. Evidence of the potential of nuclear morphometry and DNA cytometry in FNAB of the breast. **Jamahiriya Medical Journal** 2008; 8(1): 10-14.
47. Buhmeida A, **Elzagheid A**, Collan Y, Syrjanen K, Pyrhonen S. Expression of the cell-cell adhesion molecule β -catenin in colorectal carcinomas and their metastases. **APMIS** 2008; 116 (1):1-9.
48. **Elzagheid A**, korkeila E, Bendardaf R, Buhmeida A, Heikkila S, Syrjänen K, Pyrhönen S, Carpen O. Expression of Ezrin (cytovillin) predicts disease-

- specific survival and survival with metastases in advanced colorectal cancer. **Human Pathology** 2008; 39(12):1737-43.
49. **Elzagheid A**, Madarova J, Kuopio T, Kronqvist Pauliina, Ehrmann Jiri, Collan Yrjo. Immunohistochemical detection of cyclin dependent kinase inhibitor p27 does not have prognostic significance in breast cancer. **Jamahiriya Medical Journal** 2007; 7(2): 128-131.
 50. Bendardaf R, **Elzagheid A**, Ålgars A, korkeila E, Ristamäki R, Collan Y, Syrjänen K, Pyrhönen S. Thymidylate synthase expression in the primary colorectal tumors correlate with its expression in metastases. **Scandanavian Journal of Gastroenterology** 2007; 42(4):471-6.
 51. **Elzagheid A**, Kuopio T, Pyrhönen S, Collan Y. Lymph node status as a guide to selection of available prognostic markers in breast cancer: the clinical practice of the future **Diagnostic Pathology** 2006; 1:41 (Highly accessed).
 52. **Elzagheid A**, Bendardaf R, Syrjänen K, Collan Y, Pyrhönen S. E-cadherin expression significantly correlation with the response to chemotherapy in locally advanced and metastatic colorectal carcinoma. **Jamahiriya Medical Journal** 2006; 6(2): 120-123.
 53. Bendardaf R, Ålgars A, **Elzagheid A**, Korkeila E, Ristamäki R, Lamlum H, Collan Y, Syrjänen K, Pyrhönen S. Comparison of CD44 expression in primary tumours and metastases of colorectal cancer. **Oncology reports** 2006; 16 (4):741-46.
 54. **Elzagheid A**, Ålgars A, Bendardaf R, Lamlum H, Ristamäki R, Collan Y, Syrjänen K, Pyrhönen S. E-cadherin expression pattern in primary colorectal carcinomas and their metastases reflects disease outcome. **World Journal of Gastroenterology** 2006; 12 (27): 4304-4309.
 55. Bendardaf R, Lamlum H, **Elzagheid A**, Ristamaki R, Pyrhonen S. Thymidylate synthase expression levels: A prognostic and predictive role in advanced colorectal cancer. **Oncology reports** 2005; 14(3):657-62.
 56. Bendardaf R, **Elzagheid A**, Lamlum H, Ristamaki R, Collan Y, Pyrhonen S. Cell adhesion molecules (E-Cadherin, CD44s and CD44v6) and tumour differentiation in advanced colorectal cancer. **Oncology Reports** 2005; 13(5):831-835.
 57. **Elzagheid A**, Kuopio T, Collan Y. Implementation of DNA cytometric measurements in FNAB diagnostics of breast disease. **Cancer** 2004; 102(6):380-8.
 58. Zhou Q, **Elzagheid A**, Jalava P, Sundfors C, Huang D, Syvaaja JE, Collan Y. Highly conserved region of the catalytic unit of human DNA polymerase epsilon in breast cancer. **Experimental Oncology** 2003; 25(3): 206-210.
 59. **Elzagheid A**, Kuopio T, Korhonen AM, Collan Y. Apocrine change in FNAB: nuclear morphometry and DNA cytometry. **APMIS** 2003; 111:898-904.
 60. **Elzagheid A**, Collan Y. Fine needle aspiration biopsy of the breast: Value of nuclear morphometry after different sampling methods. **Analytical and Quantitative Cytology and Histology** 2003; 25: 73-80.
 61. **Elzagheid A**, Collan Y. Dependency of DNA-histograms on the sampling technique of FNAB of breast cells. **Analytical Cellular Pathology** 2002; 24: 159-165.

62. **Elzagheid A**, Kuopio T, Ilmen M, Collan Y. Prognostication of breast cancer by quantitation of E-cadherin: the methodology and clinical relevance. **Histopathology** 2002; 41: 127-133.

Other Scientific Publications

1. **Elzagheid A**. Application of E-cadherin immunostaining, DNA image cytometry, and nuclear morphometry in diagnosis and prognosis of breast diseases. Finnish breast cancer group. No.2, 2004, P.20-22.
2. **Elzagheid A**. Application of E-cadherin immunostaining, DNA image cytometry, and nuclear morphometry in diagnosis and prognosis of breast diseases. 2003, Doctoral thesis, University of Turku, Finland. *Annales Universitatis Turkuensis*, ser D 586, pp. 108.
3. Collan Y, Kujari H, Buhmeida A, **Elzagheid A**, Kronqvist P, Zhou Q. Common types of human cancer: current views of prevention, causes, and treatment of breast cancer and prostate cancer. Proceedings of XIV Paulo Foundation Symposium 1999. Turku (ed) 2001.
4. **Elzagheid A**, ElFiruri O. The Prognostic and Predictive value of Immunohistochemistry Markers in stage II Colorectal Carcinoma. **2017**, Thesis, Authority of Natural Science Research and Technology. **pp. 171**.

Abstracts:

1. Glesa S, Emaetig F, Alragig M, Elnattah N, Jaber M, Obida E, ElFagieh M, Elzagheid A. Prognostic significance of surviving and living expression in the primary breast cancer and their lymph node metastasis. **Surgery Curr Res 2018, 8**.
2. Said W, Emaetig F, El Gehani K, Eldarat T, Buhmeida A, **Elzagheid A**, El-Faitori O. (P0148) B-catenin as a prognostic marker in Libyan patients with Prostatic Carcinoma. **EJC. May 2014; 50, supplement 4; P:e51**.
3. Emaetig F, El Gehani K, El Nahwie H, Buhmeida A, **Elzagheid A**. (P0150) Survivin Expression in Renal Cell Carcinoma and Its Correlation with Clinicopathological Parameters. **EJC. May 2014; 50, supplement 4; P:e51**.
4. Aljafil R, Emaetig F, Sassi S, El Hasadi I, El Gehani K, Buhmeida A, El-Faitori O, **Elzagheid A**. (P0167) E-cadherin expression in Libyan patients with colorectal carcinoma. **EJC. May 2014; 50, supplement 4; P:e57**.
5. **Elzagheid A**, Korkeila E, Bendardaf R, Buhmeida A, Heikkila S, Syrjänen K, Pyrhönen S, Carpen O. Prognostic significance of Ezrin in advanced colorectal cancer. **LJM. 2007; 2(2), supplement; P:13**.
6. Bendardaf R, **Elzagheid A**, Ristamäki R, Syrjänen K, Pyrhönen S. Expression of thymidylate synthase in primary colorectal carcinoma and their corresponding metastases. **JCO. 2006; 24(18S):13587**.
7. Zhou Q, Collan Y, **Elzagheid A**, Sundstrom J, Effati R, Talvinen K, Pospiech H, Suvaioja J: Human DNA polymerase epsilon in human breast and colorectal cancer. **Mod Pathol. 2006; 19: Suppl. 3, 74**.
8. **Elzagheid A**, Ålgars A, Bendardaf R, Lamlum H, Ristamäki R, Collan Y, Syrjänen K, Pyrhönen S. E-cadherin expression pattern in primary colorectal carcinomas and their metastases reflects disease outcome. **Virchows Arch. 2005; 447(2), P:285-286**.
9. **Elzagheid A**, Bendardaf R, Collan Y, Pyrhonen S. E-cadherin, CD44S and CD44V6

- correlate with tumour differentiation in colorectal cancer. **Ann Oncol.** 2005; 16; Supplement 3, (P iii39).
10. Bendardaf R, Lamlum H, **Elzagheid A**, Ristamaki R, Pyrhonen S. Thymidylate synthase expression levels: A prognostic and predictive role in advanced colorectal cancer. **Ann Oncol.** 2005; 16; Supplement 2, (P ii284).
 11. Collan Y, **Elzagheid A**, Kuopio T. DNA cytometry helping fine needle aspiration biopsy diagnosis of the breast. **Pathol Int.** 2004; 54(s2), (A43-44).
 12. **Elzagheid A**, Collan Y, Kuopio T. Prognostication of breast cancer by quantitation of E-cadherin: the methodology and clinical relevance. **Anal Cell Pathol.** 2001; 22, (1,2).
 13. Collan Y, Jalava P, **Elzagheid A**, Buhmeida A, Aaltonen M, Kronqvist P, Kuopio T. Problem solving in modern pathology. **Electronic J Pathol.** 2000 6(3).

REFERENCES

Olli Carpen, M.D., Ph.D
Professor of Pathology
Department of Pathology,
University of Turku, Finland
E-mail: olli.carpen@utu.fi

Prof. Kari Syrjänen, MD, PhD, FIAC
Chief Medical Director
BiohitOyj
Laippatie 1, FI-00880 Helsinki, Finland
Tel: +358 9 773 86 304, Mobile: +358 40 556 6810
kari.syrjanen@biohit.fi, www.biohit.fi

Nureddin Ashammakhi, MD, PhD,
Associate Director, Center for Minimally Invasive Therapeutics (C-MIT),
University of California, Los Angeles
Room # 4528,
California NanoSystems Institute,
570 Westwood Plaza, Los Angeles, CA 90095
E-mail: n.ashammakhi@ucla.edu